FibroGen Net Tangible Assets vs Capital Surpluse Analysis

FGEN Stock

USD 0.39 0.01 2.50%

FibroGen financial indicator trend analysis is much more than just examining FibroGen latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroGen is a good investment. Please check the relationship between FibroGen Net Tangible Assets and its Capital Surpluse accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

Net Tangible Assets vs Capital Surpluse

Net Tangible Assets vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroGen Net Tangible Assets account and Capital Surpluse. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between FibroGen's Net Tangible Assets and Capital Surpluse is -0.01. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of FibroGen, assuming nothing else is changed. The correlation between historical values of FibroGen's Net Tangible Assets and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of FibroGen are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Tangible Assets i.e., FibroGen's Net Tangible Assets and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Capital Surpluse

Most indicators from FibroGen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroGen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.As of the 26th of November 2024, Selling General Administrative is likely to drop to about 82.7 M. In addition to that, Tax Provision is likely to drop to about 29.4 K

	2021	2022	2023	2024 (projected)
Interest Expense	2.2M	1.4M	15.5M	16.3M
Depreciation And Amortization	14.8M	10.6M	9.9M	7.2M

Interest Expense Depreciation And Amortization

FibroGen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		-0.08	0.34	0.45	0.64	0.6	-0.36	0.35	-0.59	-0.4	0.44	0.6	-0.23	0.22	0.32	-0.7	0.96	0.55	0.78	0.65	0.64	0.54	0.39	0.76	0.51	-0.34
Short Long Term Debt Total	-0.08		-0.23	-0.04	-0.11	0.16	0.41	0.4	0.07	-0.03	-0.21	0.02	0.14	0.12	-0.51	-0.29	-0.06	-0.12	0.17	0.02	-0.08	0.3	-0.32	0.08	0.13	0.69
Other Current Liab	0.34	-0.23		0.95	-0.28	0.84	-0.62	0.51	-0.03	-0.84	0.91	0.05	-0.41	-0.41	0.04	-0.03	0.34	0.43	0.67	0.71	0.42	0.79	0.18	0.75	0.9	0.11
Total Current Liabilities	0.45	-0.04	0.95		-0.22	0.93	-0.58	0.65	-0.16	-0.88	0.95	0.2	-0.36	-0.36	0.05	-0.15	0.45	0.4	0.8	0.79	0.39	0.9	0.11	0.85	0.98	0.13
Total Stockholder Equity	0.64	-0.11	-0.28	-0.22		-0.06	0.11	-0.16	-0.61	0.41	-0.16	0.54	0.08	0.57	0.52	-0.48	0.62	0.22	0.2	0.06	0.32	-0.16	0.31	0.14	-0.19	-0.57
Other Liab	0.6	0.16	0.84	0.93	-0.06		-0.6	0.64	-0.25	-0.87	0.81	0.31	-0.45	-0.24	0.01	-0.36	0.61	0.54	0.93	0.86	0.49	0.97	0.22	0.95	0.97	0.26
Property Plant And Equipment Net	-0.36	0.41	-0.62	-0.58	0.11	-0.6		0.04	0.29	0.67	-0.58	-0.3	0.73	0.4	-0.38	0.16	-0.42	-0.46	-0.55	-0.66	-0.18	-0.44	-0.47	-0.63	-0.52	0.05
Current Deferred Revenue	0.35	0.4	0.51	0.65	-0.16	0.64	0.04		0.0	-0.57	0.6	0.07	0.13	-0.27	-0.18	-0.27	0.3	0.42	0.63	0.44	0.33	0.78	-0.37	0.56	0.73	0.34
Net Debt	-0.59	0.07	-0.03	-0.16	-0.61	-0.25	0.29	0.0		0.01	-0.27	-0.99	0.36	-0.05	-0.76	0.26	-0.71	-0.07	-0.39	-0.26	0.16	-0.11	0.02	-0.37	-0.14	0.42
Retained Earnings	-0.4	-0.03	-0.84	-0.88	0.41	-0.87	0.67	-0.57	0.01		-0.78	-0.09	0.48	0.47	0.17	0.24	-0.41	-0.46	-0.74	-0.79	-0.39	-0.88	-0.15	-0.81	-0.9	-0.34
Accounts Payable	0.44	-0.21	0.91	0.95	-0.16	0.81	-0.58	0.6	-0.27	-0.78		0.29	-0.33	-0.46	0.27	-0.05	0.45	0.38	0.7	0.75	0.28	0.77	-0.02	0.78	0.88	-0.07
Cash	0.6	0.02	0.05	0.2	0.54	0.31	-0.3	0.07	-0.99	-0.09	0.29		-0.39	-0.02	0.69	-0.28	0.72	0.09	0.44	0.29	-0.18	0.18	-0.07	0.4	0.19	-0.31
Non Current Assets Total	-0.23	0.14	-0.41	-0.36	0.08	-0.45	0.73	0.13	0.36	0.48	-0.33	-0.39		0.42	-0.28	0.13	-0.43	-0.36	-0.33	-0.54	-0.11	-0.32	-0.18	-0.48	-0.35	-0.06
Non Currrent Assets Other	0.22	0.12	-0.41	-0.36	0.57	-0.24	0.4	-0.27	-0.05	0.47	-0.46	-0.02	0.42		-0.15	-0.39	0.1	-0.35	-0.06	-0.24	0.22	-0.25	0.55	-0.17	-0.31	-0.36
Other Assets	0.32	-0.51	0.04	0.05	0.52	0.01	-0.38	-0.18	-0.76	0.17	0.27	0.69	-0.28	-0.15		0.04	0.41	0.2	0.13	0.11	-0.2	-0.16	-0.01	0.13	-0.06	-0.63
Long Term Debt	-0.7	-0.29	-0.03	-0.15	-0.48	-0.36	0.16	-0.27	0.26	0.24	-0.05	-0.28	0.13	-0.39	0.04		-0.65	-0.43	-0.54	-0.5	-0.57	-0.36	-0.41	-0.54	-0.26	0.05
Cash And Short Term Investments	0.96	-0.06	0.34	0.45	0.62	0.61	-0.42	0.3	-0.71	-0.41	0.45	0.72	-0.43	0.1	0.41	-0.65		0.54	0.76	0.67	0.54	0.53	0.29	0.77	0.5	-0.32
Net Receivables	0.55	-0.12	0.43	0.4	0.22	0.54	-0.46	0.42	-0.07	-0.46	0.38	0.09	-0.36	-0.35	0.2	-0.43	0.54		0.59	0.61	0.67	0.5	0.16	0.61	0.46	0.12
Common Stock Total Equity	0.78	0.17	0.67	0.8	0.2	0.93	-0.55	0.63	-0.39	-0.74	0.7	0.44	-0.33	-0.06	0.13	-0.54	0.76	0.59		0.79	0.55	0.9	0.29	0.94	0.87	0.11
Common Stock Shares Outstanding	0.65	0.02	0.71	0.79	0.06	0.86	-0.66	0.44	-0.26	-0.79	0.75	0.29	-0.54	-0.24	0.11	-0.5	0.67	0.61	0.79		0.59	0.81	0.31	0.95	0.82	0.05
Short Term Investments	0.64	-0.08	0.42	0.39	0.32	0.49	-0.18	0.33	0.16	-0.39	0.28	-0.18	-0.11	0.22	-0.2	-0.57	0.54	0.67	0.55	0.59		0.51	0.51	0.59	0.46	-0.1
Non Current Liabilities Total	0.54	0.3	0.79	0.9	-0.16	0.97	-0.44	0.78	-0.11	-0.88	0.77	0.18	-0.32	-0.25	-0.16	-0.36	0.53	0.5	0.9	0.81	0.51		0.09	0.9	0.97	0.36
Other Current Assets	0.39	-0.32	0.18	0.11	0.31	0.22	-0.47	-0.37	0.02	-0.15	-0.02	-0.07	-0.18	0.55	-0.01	-0.41	0.29	0.16	0.29	0.31	0.51	0.09		0.31	0.1	-0.27
Other Stockholder Equity	0.76	0.08	0.75	0.85	0.14	0.95	-0.63	0.56	-0.37	-0.81	0.78	0.4	-0.48	-0.17	0.13	-0.54	0.77	0.61	0.94	0.95	0.59	0.9	0.31		0.9	0.07
Total Liab	0.51	0.13	0.9	0.98	-0.19	0.97	-0.52	0.73	-0.14	-0.9	0.88	0.19	-0.35	-0.31	-0.06	-0.26	0.5	0.46	0.87	0.82	0.46	0.97	0.1	0.9		0.25
Property Plant And Equipment Gross	-0.34	0.69	0.11	0.13	-0.57	0.26	0.05	0.34	0.42	-0.34	-0.07	-0.31	-0.06	-0.36	-0.63	0.05	-0.32	0.12	0.11	0.05	-0.1	0.36	-0.27	0.07	0.25

Click cells to compare fundamentals

FibroGen Account Relationship Matchups

FibroGen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	857.4M	826.8M	773.8M	610.1M	423.5M	665.2M
Short Long Term Debt Total	67.9M	37.7M	99.7M	89.9M	170.5M	89.2M
Other Current Liab	83.8M	118.9M	149.0M	224.8M	166.2M	84.4M
Total Current Liabilities	102.7M	163.2M	225.5M	273.6M	217.7M	128.8M
Total Stockholder Equity	516.1M	422.2M	209.1M	(21.4M)	(204.2M)	(194.0M)
Other Liab	162.8M	178.1M	212.8M	241.4M	277.6M	147.1M
Property Plant And Equipment Net	82.3M	63.3M	120.2M	100.5M	81.4M	89.5M
Current Deferred Revenue	490K	6.5M	15.9M	13.1M	12.7M	10.0M
Net Debt	(75.2M)	(640.7M)	(71.5M)	(65.8M)	56.8M	59.6M
Retained Earnings	(784.7M)	(974.0M)	(1.3B)	(1.6B)	(1.8B)	(1.7B)
Accounts Payable	6.1M	24.8M	26.1M	30.8M	18.0M	13.0M
Cash	126.3M	678.4M	171.2M	155.7M	113.7M	108.0M
Non Current Assets Total	154.9M	71.7M	299.8M	117.3M	92.0M	146.7M
Non Currrent Assets Other	11.4M	5.5M	8.0M	7.4M	5.3M	6.5M
Other Assets	9.5M	38.1M	8.0M	6.9M	1.0	0.95
Long Term Debt	17.2M	16.8M	16.8M	71.9M	64.7M	46.3M
Cash And Short Term Investments	533.8M	686.5M	405.2M	422.0M	235.6M	404.9M
Net Receivables	28.5M	41.9M	25.4M	16.3M	41.1M	26.7M
Common Stock Total Equity	854K	877K	914K	929K	1.1M	716.1K
Common Stock Shares Outstanding	86.6M	89.9M	92.3M	93.6M	97.3M	78.2M
Short Term Investments	407.5M	8.1M	234.0M	266.3M	121.9M	165.1M
Liabilities And Stockholders Equity	857.4M	826.8M	773.8M	610.1M	423.5M	665.2M
Non Current Liabilities Total	219.2M	222.2M	319.2M	338.0M	368.1M	261.8M
Other Current Assets	133.4M	10.2M	12.5M	14.1M	13.4M	19.5M
Other Stockholder Equity	1.3B	1.4B	1.5B	1.5B	1.6B	1.0B
Total Liab	322.0M	385.4M	544.7M	611.6M	585.7M	390.6M
Property Plant And Equipment Gross	82.3M	63.3M	120.2M	100.5M	253.1M	138.8M
Total Current Assets	702.5M	755.1M	474.1M	492.8M	331.6M	463.5M
Accumulated Other Comprehensive Income	(747K)	(4.5M)	(4.2M)	(5.7M)	(6.9M)	(6.5M)
Short Term Debt	12.4M	13.5M	21.9M	10.3M	14.1M	20.2M
Common Stock	877K	914K	929K	942K	988K	773.7K
Property Plant Equipment	42.7M	33.6M	120.2M	100.9M	90.8M	86.7M
Net Tangible Assets	516.1M	422.2M	209.1M	(21.4M)	(19.3M)	(18.3M)
Long Term Investments	61.1M	244K	171.6M	9.4M	5.3M	5.0M
Retained Earnings Total Equity	(715.8M)	(784.7M)	(974.0M)	(1.3B)	(1.1B)	(1.2B)
Capital Surpluse	1.2B	1.3B	1.4B	1.5B	1.7B	1.2B

Pair Trading with FibroGen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.

Moving against FibroGen Stock

0.62	MLYS	Mineralys Therapeutics,	Pair Corr
0.52	KZR	Kezar Life Sciences	Pair Corr

The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.

The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:

How To Invest In FibroGen

Details

Is FibroGen Stock a good investment?

Details

What is FibroGen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.536

Earnings Share

(1.23)

Revenue Per Share

1.758

Quarterly Revenue Growth

0.143

Return On Assets

(0.27)

The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FibroGen Net Tangible Assets vs Capital Surpluse Analysis

Net Tangible Assets vs Capital Surpluse

Net Tangible Assets vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Capital Surpluse

FibroGen fundamental ratios Correlations

FibroGen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

FibroGen fundamental ratios Accounts

Pair Trading with FibroGen

Moving against FibroGen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 0.98	Total Current Liabilities
Non Current Liabilities Total	+ 0.97	Other Liab
Total Liab	+ 0.97	Other Liab
Total Liab	+ 0.97	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Total Assets
Total Current Liabilities	+ 0.95	Other Current Liab

Cash	- 0.99	Net Debt
Total Liab	- 0.9	Retained Earnings
Non Current Liabilities Total	- 0.88	Retained Earnings
Retained Earnings	- 0.88	Total Current Liabilities
Retained Earnings	- 0.87	Other Liab
Retained Earnings	- 0.84	Other Current Liab